Inhibrx (Inhibrx) Growth Rank : 1 (As of May. 13, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Inhibrx Growth Rank?

Inhibrx has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Competitive Comparison of Inhibrx's Growth Rank

For the Biotechnology subindustry, Inhibrx's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibrx's Growth Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibrx's Growth Rank distribution charts can be found below:

* The bar in red indicates where Inhibrx's Growth Rank falls into.

Inhibrx Growth Rank Related Terms

Thank you for viewing the detailed overview of Inhibrx's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibrx (Inhibrx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Inc (NAS:INBX) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

11025 N. Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037

Website

https://www.inhibrx.com

Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.

Executives

Ole Andreas Halvorsen	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Mark Lappe	director, 10 percent owner, officer: Chief Executive Officer	11622 EL CAMINO REAL, SUITE 100, SAN DIEGO CA 92130
Brendan P. Eckelman	director, 10 percent owner, officer: Chief Scientific Officer	C/O INHIBRX, INC., 11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jon Faiz Kayyem	director, 10 percent owner	5964 LA PLACE COURT, CARLSBAD CA 92008
Dragsa 50 Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Portfolio Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Kristiina Md Vuori	director	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Klaus W. Wagner	officer: Chief Medical Officer	C/O INHIBRX, INC., 11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Kimberly Manhard	director	C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121